Literature DB >> 11242598

Evaluation of diagnostic criteria in polycythemia vera.

T C Pearson1.   

Abstract

There is no single diagnostic marker for the only known type of primary acquired erythrocytosis, polycythemia vera (PV). The Polycythemia Vera Study Group (PVSG) used a combination of major and minor diagnostic criteria. However, these guidelines have some limitations and in the presence of newer diagnostic tools, have been re-evaluated. The recommendations of the Radionuclide Panel of the International Council for Standardization Hematology based on surface area are recommended over red blood cell mass (RCM) mL/kg expressions. Absolute erythrocytosis can be assumed in males and females with packed cell volume (PCV) values greater than 0.60 and greater than 0.56, respectively. A satisfactory strategy of investigation for a secondary erythrocytosis must be used. Hypoxemia, as well as renal and hepatic pathology, must be excluded. In unexplained absolute erythrocytoses, pO(2)(50) values and serum erythropoietin (EPO) levels should be examined. The latter can be disappointing in the confirmation of a secondary erythrocytosis, but elevated values contraindicate a diagnosis of a primary erythrocytosis. Establishment of a clonal marrow population supports a diagnosis of PV. Thus an acquired karyotypic abnormality is a major criterion. Palpable splenomegaly remains an important diagnostic marker. Scanning techniques to demonstrate splenic enlargement should be used with caution. Allowance must be made for interobserver and intraobserver differences and variation in normal spleen size with age and size of the subject. Splenomegaly demonstrated in this way should be taken as a minor criterion. An increased neutrophil count (>10 x 10(9)/L and >12.5 x 10(9)/L in smokers) is readily measurable and should replace total white blood cell count. The error in measurement of neutrophil alkaline phosphatase (NAP) score is large, making it an unsuitable diagnostic criterion. Neutrophil and platelet counts (>400 x 10(9)/L) should be taken as separate minor criteria. Endogenous erythroid colonies (EEC) grown from the peripheral blood have been used as a marker of PV, but it is an expensive technique that is not standardized and not totally specific for PV. Low serum EPO values found in the majority of patients with PV should hold a linked minor criterion position with EEC. Expert opinions should be obtained if bone marrow histology is to be used in the diagnosis of PV, but histology holds an important role in confirming the diagnosis. Semin Hematol 38(suppl 2):21-24. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2001        PMID: 11242598     DOI: 10.1016/s0037-1963(01)90136-2

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  10 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 2.  Best practice in primary care pathology: review 3.

Authors:  W S A Smellie; J Forth; D Bareford; P Twomey; M J Galloway; E C M Logan; S R S Smart; T M Reynolds; C Waine
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  The role of parathyroidectomy in JAK2 mutation negative polycythemia vera.

Authors:  Afif N Kulaylat; Eric E Jung; Brian D Saunders
Journal:  Int J Hematol       Date:  2014-09-11       Impact factor: 2.490

Review 4.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

5.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

6.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 7.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

8.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

9.  Aberrant phenotypes of transgenic mice expressing dimeric human erythropoietin.

Authors:  Seong-Jo Yun; Purevjargal Naidansuren; Bo-Woong Sim; Jong-Ju Park; Cha-Won Park; Tseeleema Nanjidsuren; Myung-Hwa Kang; Sue-Yun Hwang; Jong-Taek Yoon; Kwan-Sik Min
Journal:  Reprod Biol Endocrinol       Date:  2012-01-27       Impact factor: 5.211

10.  Hemoglobin concentration, total hemoglobin mass and plasma volume in patients: implications for anemia.

Authors:  James M Otto; James O M Plumb; Eleri Clissold; Shriya B Kumar; Denis J Wakeham; Walter Schmidt; Michael P W Grocott; Toby Richards; Hugh E Montgomery
Journal:  Haematologica       Date:  2017-06-08       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.